FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885406411> ?p ?o ?g. }

• W2885406411 endingPage "272" @default.
• W2885406411 startingPage "LB" @default.
• W2885406411 abstract "Abstract Introduction: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and has one of the fastest growing incidence among cancers. Aberrant FGF19-FGFR4 signaling occurs in 10-30% of HCC patients and drives tumor development and progression. Pan-FGFR inhibitors are associated with hyperphosphatemia in clinic due to inhibition of FGFR1. Therefore, selectively targeting FGFR4 may render a safer treatment approach with improved clinical benefits. Using advanced computation-aided structural analysis and medicinal chemistry design, we have discovered a novel and highly selective small molecular FGFR4 inhibitor, ABSK-011, demonstrating robust anti-tumor activity in hepatocellular carcinoma models. Method: ABSK-011 was evaluated in biochemical Caliper assay and Celltiter-Glo assay for its inhibition on FGFR4 enzymatic and cellular activities. Its selectivity against other FGFR family members was analyzed through related biochemical, cellular, and KinomeScan profiling assays. The pharmacokinetics (PK) profile of ABSK-011 was characterized across various species of animals including mouse, rat and dog. Efficacy studies were conducted in two HCC xenograft models, and preliminary toxicity profile was also evaluated. Results: ABSK-011 inhibits FGFR4 with IC50 &lt; 10 nM in biochemical assay and exhibits at least 50 fold selectivity against other FGFR kinases. The strong selectivity arises from the ability of ABSK-011 to irreversibly modify Cys552, a residue within the active site of FGFR4 that is not conserved among other FGFR kinases. ABSK-011 also shows greater than 800-fold selectivity against other RTK members. In HCC cells with autocrine production of FGF19, ABSK-011 inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. HCC cell lines harboring amplification and overexpression of FGF19 are uniquely sensitive to growth inhibition by ABSK-011 (EC50 &lt; 50 nM) compared with cancer cell lines with FGFR1 dependence (EC50 &gt; 2000 nM), confirming selectivity for FGFR4 over FGFR1. In vivo PK study demonstrated high exposure and superior DMPK profile of ABSK-011 in mouse, rat and dog. In preclinical in vivo studies, oral administration of ABSK-011 strongly inhibits the growth and induces regressions of subcutaneous xenograft tumors dependent upon FGFR4 activity. Suppression of tumor growth is dose dependent and well correlated with pharmacodynamic inhibition of FGFR4 signaling. Safety studies showed that ABSK-011 has no inhibition on CYP family members, hERG, etc. Conclusion: ABSK-011, presented here by Abbisko Therapeutics, is a highly potent, selective, and oral-available small molecular FGFR4 inhibitor. Its superior profile supports fast-track preclinical development. Citation Format: Zhui Chen. Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-272." @default.
• W2885406411 created "2018-08-22" @default.
• W2885406411 creator A5057951270 @default.
• W2885406411 date "2018-07-01" @default.
• W2885406411 modified "2023-09-25" @default.
• W2885406411 title "Abstract LB-272: Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma" @default.
• W2885406411 doi "https://doi.org/10.1158/1538-7445.am2018-lb-272" @default.
• W2885406411 hasPublicationYear "2018" @default.
• W2885406411 type Work @default.
• W2885406411 sameAs 2885406411 @default.
• W2885406411 citedByCount "2" @default.
• W2885406411 countsByYear W28854064112019 @default.
• W2885406411 countsByYear W28854064112023 @default.
• W2885406411 crossrefType "journal-article" @default.
• W2885406411 hasAuthorship W2885406411A5057951270 @default.
• W2885406411 hasConcept C170493617 @default.
• W2885406411 hasConcept C184235292 @default.
• W2885406411 hasConcept C185592680 @default.
• W2885406411 hasConcept C2775936931 @default.
• W2885406411 hasConcept C2778019345 @default.
• W2885406411 hasConcept C2778695046 @default.
• W2885406411 hasConcept C502942594 @default.
• W2885406411 hasConcept C55493867 @default.
• W2885406411 hasConcept C66400584 @default.
• W2885406411 hasConcept C71924100 @default.
• W2885406411 hasConcept C74373430 @default.
• W2885406411 hasConcept C82867764 @default.
• W2885406411 hasConcept C98274493 @default.
• W2885406411 hasConceptScore W2885406411C170493617 @default.
• W2885406411 hasConceptScore W2885406411C184235292 @default.
• W2885406411 hasConceptScore W2885406411C185592680 @default.
• W2885406411 hasConceptScore W2885406411C2775936931 @default.
• W2885406411 hasConceptScore W2885406411C2778019345 @default.
• W2885406411 hasConceptScore W2885406411C2778695046 @default.
• W2885406411 hasConceptScore W2885406411C502942594 @default.
• W2885406411 hasConceptScore W2885406411C55493867 @default.
• W2885406411 hasConceptScore W2885406411C66400584 @default.
• W2885406411 hasConceptScore W2885406411C71924100 @default.
• W2885406411 hasConceptScore W2885406411C74373430 @default.
• W2885406411 hasConceptScore W2885406411C82867764 @default.
• W2885406411 hasConceptScore W2885406411C98274493 @default.
• W2885406411 hasIssue "13_Supplement" @default.
• W2885406411 hasLocation W28854064111 @default.
• W2885406411 hasOpenAccess W2885406411 @default.
• W2885406411 hasPrimaryLocation W28854064111 @default.
• W2885406411 hasRelatedWork W1858027700 @default.
• W2885406411 hasRelatedWork W2017637322 @default.
• W2885406411 hasRelatedWork W2338474440 @default.
• W2885406411 hasRelatedWork W2593458599 @default.
• W2885406411 hasRelatedWork W2739980551 @default.
• W2885406411 hasRelatedWork W2741443984 @default.
• W2885406411 hasRelatedWork W2885736997 @default.
• W2885406411 hasRelatedWork W3133722275 @default.
• W2885406411 hasRelatedWork W4200242790 @default.
• W2885406411 hasRelatedWork W4237713599 @default.
• W2885406411 hasVolume "78" @default.
• W2885406411 isParatext "false" @default.
• W2885406411 isRetracted "false" @default.
• W2885406411 magId "2885406411" @default.
• W2885406411 workType "article" @default.